S0221
|
SWOG
|
Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S0226
|
SWOG
|
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0227
|
SWOG
|
Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent; Persistent; or Metastatic Carcinoma of the Cervix
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0232
|
SWOG
|
Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0303
|
SWOG
|
A Phase III Trial of Modified FOLFOX6 Versus CAPOX; with Bevacizumab (NSC-704865) or Placebo; as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0307
|
SWOG
|
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0309
|
SWOG
|
Myeloma Specimen Repository Protocol Ancillary
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0334
|
SWOG
|
Myeloma Specimen Repository Protocol Ancillary
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0337
|
SWOG
|
A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0347
|
SWOG
|
A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|